Developing a Rat Duodenal Monolayer Model with Barrier Function for ADME Assays using Rat Organoids: Insights from Scientific Reports
In recent years, there has been a growing need for reliable in vitro models that can accurately predict the absorption, distribution, metabolism, and excretion (ADME) of drugs in the human body. Traditional cell culture models often fail to mimic the complex physiological conditions found in vivo, leading to inaccurate predictions and potential drug failures during clinical trials. However, recent advancements in organoid technology have opened up new possibilities for developing more realistic and functional in vitro models.
One such breakthrough comes from a study published in Scientific Reports, where researchers successfully developed a rat duodenal monolayer model with barrier function using rat organoids. This model holds great promise for studying drug absorption and metabolism in the small intestine, a crucial site for drug interactions and bioavailability.
The researchers started by isolating and culturing rat intestinal crypts, which contain stem cells capable of self-renewal and differentiation into various cell types. These crypts were then embedded in a specialized extracellular matrix and cultured under specific conditions that promote the formation of three-dimensional organoids. These organoids closely resemble the structure and function of the small intestine, making them an ideal starting point for developing a duodenal monolayer model.
To create the monolayer model, the researchers carefully dissociated the organoids into single cells and seeded them onto permeable supports. The cells were then allowed to grow and differentiate into a monolayer, forming tight junctions that mimic the barrier function of the intestinal epithelium. This barrier function is crucial for regulating the transport of drugs across the intestinal epithelium and plays a significant role in drug absorption.
The researchers validated the functionality of their model by assessing its barrier integrity using transepithelial electrical resistance (TEER) measurements. TEER is a widely used technique to evaluate the tightness of epithelial barriers, with higher TEER values indicating a more intact and functional barrier. The rat duodenal monolayer model exhibited significantly higher TEER values compared to traditional cell culture models, indicating its superior barrier function.
Furthermore, the researchers demonstrated the model’s ability to predict drug absorption by performing ADME assays using known substrates of drug transporters. They observed that the monolayer model accurately predicted the transport characteristics of these substrates, suggesting its potential for studying drug-drug interactions and predicting drug bioavailability.
The development of this rat duodenal monolayer model with barrier function using rat organoids represents a significant advancement in the field of in vitro ADME assays. Its ability to mimic the physiological conditions of the small intestine, including barrier function and drug transport, makes it a valuable tool for drug development and screening.
This model holds great promise for improving the accuracy of preclinical drug testing, reducing the reliance on animal models, and ultimately increasing the success rate of drug candidates in clinical trials. Additionally, it provides a platform for studying the mechanisms underlying drug absorption and metabolism in the small intestine, leading to a better understanding of drug pharmacokinetics.
In conclusion, the development of a rat duodenal monolayer model with barrier function using rat organoids represents a significant step forward in the field of in vitro ADME assays. This model offers a more physiologically relevant and functional alternative to traditional cell culture models, allowing for more accurate predictions of drug absorption and metabolism. With further advancements in organoid technology, we can expect to see even more sophisticated and reliable in vitro models that will revolutionize drug development and improve patient outcomes.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: Plato Data Intelligence.